OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma

Pancreatic cancer has a high morbidity and mortality with the majority being PC ductal adenocarcinomas (PDAC). Whole genome sequencing provides a wide description of genomic events involved in pancreatic carcinogenesis and identifies putative biomarkers for new therapeutic approaches. However, currently, there are no approved treatments targeting driver mutations in PDAC that could produce clinical benefit for PDAC patients. A proportion of 5–10% of PDAC have a hereditary origin involving germline variants of homologous recombination genes, such as Mismatch Repair (MMR), STK11 and CDKN2A genes. Very recently, BRCA genes have been demonstrated as a useful biomarker for PARP-inhibitor (PARPi) treatments. In this study, a series of 21 FFPE PDACs were analyzed using OncoPan®, a strategic next-generation sequencing (NGS) panel of 37 genes, useful for identification of therapeutic targets and inherited cancer syndromes. Interestingly, this approach, successful also on minute pancreatic specimens, identified biomarkers for personalized therapy in five PDAC patients, including two cases with HER2 amplification and three cases with mutations in HR genes (BRCA1, BRCA2 and FANCM) and potentially eligible to PARPi therapy. Molecular analysis on normal tissue identified one PDAC patient as a carrier of a germline BRCA1 pathogenetic variant and, noteworthy, this patient was a member of a family affected by inherited breast and ovarian cancer conditions. This study demonstrates that the OncoPan® NGS-based panel constitutes an efficient methodology for the molecular profiling of PDAC, suitable for identifying molecular markers both for therapy and risk assessment. Our data demonstrate the feasibility and utility of these NGS analysis in the routine setting of PDAC molecular characterization.

[1]  F. Jiao,et al.  Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer , 2022, EBioMedicine.

[2]  Koji Tanaka,et al.  HER2-positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum: A case report , 2021, World journal of gastroenterology.

[3]  C. Iacobuzio-Donahue,et al.  Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. , 2021, Journal of the National Cancer Institute.

[4]  Yanlin Huang,et al.  A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer , 2021, BMC cancer.

[5]  M. Reni,et al.  Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort , 2021, ESMO open.

[6]  C. Cella,et al.  Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. , 2019, Cancer treatment reviews.

[7]  Walter G. Park,et al.  Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium , 2019, Gut.

[8]  F. Sessa,et al.  Universal screening to identify Lynch syndrome: two years of experience in a Northern Italian Center , 2019, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[9]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[10]  A. Lucas,et al.  Familial Pancreatic Ductal Adenocarcinoma. , 2019, The American journal of pathology.

[11]  E. Petricoin,et al.  Molecular Profiling of Pancreatic Cancer Patients—Response , 2018, Clinical Cancer Research.

[12]  L. Neumayer,et al.  Pancreatic cancer as a sentinel for hereditary cancer predisposition , 2018, BMC Cancer.

[13]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[14]  L. Terracciano,et al.  Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance , 2018, Clinical Cancer Research.

[15]  J. Cicenas,et al.  JNK, p38, ERK, and SGK1 Inhibitors in Cancer , 2017, Cancers.

[16]  M. Kloor,et al.  Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer , 2017, Cold Spring Harbor molecular case studies.

[17]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[18]  S. Kakar,et al.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Kakar,et al.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. , 2016, Archives of pathology & laboratory medicine.

[20]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[21]  A. Vanoli,et al.  TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer , 2016, Virchows Archiv.

[22]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[23]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[24]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[25]  P. Queirolo,et al.  CDKN2A is the main susceptibility gene in Italian pancreatic cancer families , 2012, Journal of Medical Genetics.

[26]  P. Scardino,et al.  Susceptibility Loci Associated with Prostate Cancer Progression and Mortality , 2010, Clinical Cancer Research.

[27]  Changanamkandath Rajesh,et al.  Functional characterization of the RAD51D E233G genetic variant , 2009, Pharmacogenetics and genomics.

[28]  M. J. van de Vijver,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.